A5061095757- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
Renji Hospital
2024-2025
Shanghai Jiao Tong University
2024-2025
Cell Biotech (South Korea)
2022
Grace (United States)
2022
Fudan University Shanghai Cancer Center
2019
Background Chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation (BCMA) have been used as an effective therapy against relapsed/refractory multiple myeloma (MM). However, the relapse rates in these patients are still high, which may be related to poor quality of after chemotherapies. The case reported here demonstrated effectiveness and safety first-line anti-BCMA CAR-T cell for high-risk MM patients, even frailty with comorbidities. Case presentation A 75-year-old woman was...
Background: CD19 targeted autologous CAR-T therapies have been approved for the treatment of r/r B-ALL and greatly improved outcome. However, some patients may not be eligible to receive CAR-T. TruUCAR™ GC502 is an allogeneic, universal product with CD19/CD7 dual directed CAR. Preclinical data were reported at ASH 2021 (Abstract 148500). Aims: Here, we report early clinical results from a phase I open-label, non-randomized, prospective investigator initiate trial (IIT) in evaluate safety...